Replimune Group, Inc. held its annual meeting of stockholders on September 15, 2026, where shareholders approved an amendment to increase the authorized number of common shares from 150 million to 300 million. The Company filed a Certificate of Amendment with the Delaware Secretary of State on that date, making the change effective immediately. Additionally, stockholders ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2027, and approved a non-binding advisory resolution on executive compensation. The company operates in the biotechnology industry, focusing on the development of immunotherapies for cancer.

Replimune Group, Inc. announced the FDA accelerated approval of TUDRIQEV (vusolimogene oderparepvec-wtpg) in combination with nivolumab for unresectable advanced cutaneous melanoma following PD-1 progression, with a commercial launch anticipated within 60 days. The company completed a $150 million equity financing to support the launch and its ongoing IGNYTE-3 confirmatory trial, bringing total cash resources to approximately $336 million. For the fiscal first quarter ended June 30, 2026, Replimune reported a net loss of $69.8 million, with R&D expenses at $49.3 million and SG&A expenses at $19.0 million. The company also appointed Michelle DiNapoli as Chief Commercial Officer effective August 18, 2026. Replimune Group, Inc. is a commercial-stage biotechnology company pioneering the development of novel oncolytic immunotherapies.

Replimune Group, Inc. entered into an underwriting agreement to issue and sell 9,701,490 shares of common stock and pre-funded warrants for 2,736,340 additional shares at a combined offering price of approximately $12.06 per share. The transaction is expected to generate net proceeds of roughly $140.5 million after deducting underwriting discounts and estimated expenses. Closing is anticipated on or about August 11, 2026. This amendment corrects the beneficial ownership limitations for the pre-funded warrants previously disclosed in an earlier filing.

Replimune Group, Inc. priced an underwritten public offering of 9,701,490 shares of common stock at $12.06 per share and pre-funded warrants for 2,736,340 additional shares at $12.0599 each. The transaction generates approximately $150 million in gross proceeds and $140.5 million in net proceeds after deducting underwriting discounts and offering expenses. Leerink Partners LLC, J.P. Morgan Securities LLC, and Cantor Fitzgerald & Co. served as bookrunning managers. Closing is expected on August 11, 2026. Replimune Group, Inc. operates in the biotechnology industry, developing novel oncolytic immunotherapies for cancer treatment.

On August 6, 2026, the U.S. Food and Drug Administration granted accelerated approval for TUDRIQEV (vusolimogene oderparepvec-wtpg) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma who progressed on an anti-PD-1 antibody-based regimen. The approval is based on an objective response rate of 24.2% and a median duration of response of 14.1 months observed in the IGNYTE trial's efficacy-evaluable population of 91 patients. Continued approval remains contingent upon verification of clinical benefit in the ongoing confirmatory Phase 3 trial, IGNYTE-3. Replimune Group, Inc. operates as a commercial-stage biotechnology company pioneering novel oncolytic immunotherapies for cancer treatment.

On July 30, 2026, the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10 to 3 that efficacy results from the IGNYTE study for Replimune’s RP1 (vusolimogene oderparepvec) in combination with nivolumab are evaluable and clinically meaningful. This favorable outcome supports the BLA resubmission for advanced melanoma patients who progressed on prior anti-PD-1 therapy, with a target FDA action date of August 2, 2026. Replimune Group, Inc. is a clinical-stage biotechnology company pioneering novel oncolytic immunotherapies.